Search Recent Articles

Search Recent ArticlesOTS2021-10-26T10:53:41+00:00

Subscribe to our Newsletter

Oligonucleotide Therapeutics Society

3960 W Point Loma Blvd, Suite H
Box 346
San Diego, CA 92110

info@oligotherapeutics.org

Terms & Conditions

Resources

Recent Articles
Webinars
Become A Member or Renew Membership
Employer Registration / Login
Contact Us

Subscribe in a reader

Stay Connected

Search

Enter Username or Email Address:
Password:
Forgot Password? | Sign Up

Save Password

First Name *
Last Name *
Username *
Email *
Password *
Confirm Password *
Phone: *
Organization Name
Select Sectors

Reload
Already have an account? Login

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

Search Recent Articles

Search Posts

Category

From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis

President’s Pick Article – August 2023

Investigating the Biology and Potential of CircRNA

ASO activity and distribution after LNP delivery

Interview with Leonora Abdullahu, PhD

Subscribe to our Newsletter

Resources

Stay Connected

Search

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

October 11–14, 2026 | Denver, CO

Stay Updated!

OTS Webinars

Events Calendar

Annual Meetings

Search Recent Articles

Search Posts

Category

From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis

President’s Pick Article – August 2023

Investigating the Biology and Potential of CircRNA

ASO activity and distribution after LNP delivery

Interview with Leonora Abdullahu, PhD

Subscribe to our Newsletter

Resources

Stay Connected

Search

Login to your account

Reset Password

Signup to your Account

Answers

Job Alerts

Account Activation